Rapaflo (Watson) Laboratories-Open for enrollment
A prospective, multi center evaluation of the urodynamic benefits of Silodosin in men with bladder outlet obstruction associated with benign prostatic hyperplasia.
Inclusion Criteria:
- Age > 45 years
- Has a diagnosis of benign prostatic hyperplasia(BPH)
- Has experienced lower urinary tract symptoms associated with BPH for at least 3 months prior to screening.
- Has a bladder outlet obstruction index (BOOI) > 40 from urodynamic assessment